TG-4050

N/A

Report date: 2026/04/20 20:01:59

Base Information

Drug NameTG-4050
Drug Alias NameNeoantigen directed cancer vaccine (Transgene)myvacTG-4050
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsFallopian Tube NeoplasmsHead and Neck NeoplasmsPeritoneal Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited KingdomFrance +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesTransgene Sa
China Registration ClassN/A

Develop Information

Active CompaniesBostonGene CorpNec CorpTransgene Sa
Inactive CompaniesN/A
Active IndicationsFallopian Tube NeoplasmsHead and Neck NeoplasmsPeritoneal Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A